Introduction

ChinaSCInet spinal cord injuries stem cell clinical trials

ChinaSCInet spinal cord injuries stem cell clinical trials

[pullquote align=”right”]”This will convince the doctors of the world that they do not need to tell patients ‘you will never walk again’,”US-based Dr Wise Young, chief executive officer of ChinaSCINet.[/pullquote]

After progress in a second round of tests using stem cells to regrow nerve fibres, the China Spinal Cord Injury Network (ChinaSCINet) has applied for regulatory approval in China for a third and final phase, which it hopes to start in the autumn.

Umbilical cord blood mononuclear cells were injected into the damaged spines of 20 patients to help regenerate nerves, while lithium is used to promote the growth of the nerve fibres.

The phase III trial will involve 120 patients in China and another 120 across India, Norway and the United States.

Read more…  | ChinaSCINet press release  | More info and discussion on CareCure forums